SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

240

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 1, 2027

Study Completion Date

December 1, 2027

Conditions

Hepatobiliary MalignancyFluoxetineAnxiety DisordersDepression Disorders

Interventions

DRUG

Fluoxetine (drug)

Fluoxetine: Maintain at 20mg per day, orally, until disease progression or intolerance

DRUG

Placebo

Placebo: 1 placebo tablet per day for maintenance, orally.

All Listed Sponsors

lead

First Affiliated Hospital of Wenzhou Medical University

OTHER